OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. 744-759
Open Access | Times Cited: 16
Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. 744-759
Open Access | Times Cited: 16
Showing 16 citing articles:
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
Michael Hallek
American Journal of Hematology (2025)
Open Access | Times Cited: 2
Michael Hallek
American Journal of Hematology (2025)
Open Access | Times Cited: 2
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 8, pp. 748-762
Closed Access
Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 8, pp. 748-762
Closed Access
Evidence-based investigation of the efficacy and safety of venetoclax-containing regimens versus chemoimmunotherapy in chronic lymphocytic leukemia
Pu Yao, Jiao Zhang, Xiaowen Wang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Pu Yao, Jiao Zhang, Xiaowen Wang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (English Edition) (2025)
Closed Access
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (English Edition) (2025)
Closed Access
Risk-stratification in frontline CLL therapy: standard of care
Eugen Tausch, Christof Schneider, Stephan Stilgenbauer
Hematology (2024) Vol. 2024, Iss. 1, pp. 457-466
Closed Access | Times Cited: 4
Eugen Tausch, Christof Schneider, Stephan Stilgenbauer
Hematology (2024) Vol. 2024, Iss. 1, pp. 457-466
Closed Access | Times Cited: 4
Venetoclax and beyond: New Horizons in CLL and AML therapy
Matteo Molica, Salvatore Perrone
Expert Review of Anticancer Therapy (2025)
Closed Access
Matteo Molica, Salvatore Perrone
Expert Review of Anticancer Therapy (2025)
Closed Access
Guía para el diagnóstico y el tratamiento de la leucemia linfocítica crónica y el linfoma linfocítico de células pequeñas del Grupo Español de Leucemia Linfocítica Crónica (GELLC)
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (2025)
Closed Access
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (2025)
Closed Access
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics
Britten Gordon, Jennifer A. Woyach
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-9
Closed Access
Britten Gordon, Jennifer A. Woyach
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-9
Closed Access
Comparative efficacy of venetoclax-based regiments in the management of chronic lymphocytic leukemia: a systematic review and metanalysis
Abdur Jamil, Shehroz Aslam, Rida Riaz, et al.
Annals of Hematology (2025)
Open Access
Abdur Jamil, Shehroz Aslam, Rida Riaz, et al.
Annals of Hematology (2025)
Open Access
Risikoadaptierte Erstlinientherapie der chronischen lymphatischen Leukämie
Moritz Fürstenau, Barbara Eichhorst
Deleted Journal (2025)
Closed Access
Moritz Fürstenau, Barbara Eichhorst
Deleted Journal (2025)
Closed Access
Too frail or not too frail? Prognosis and treatment options in older CLL patients
Florian Simon
memo - Magazine of European Medical Oncology (2025)
Open Access
Florian Simon
memo - Magazine of European Medical Oncology (2025)
Open Access
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment
Annalisa Arcari, Lucia Morello, Elena Borotti, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3483-3483
Open Access | Times Cited: 2
Annalisa Arcari, Lucia Morello, Elena Borotti, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3483-3483
Open Access | Times Cited: 2
Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
M. S. Davids, Ke Lin, Amir I. Mohamed, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
M. S. Davids, Ke Lin, Amir I. Mohamed, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?
Kerry A. Rogers, Jennifer A. Woyach
Hematology (2024) Vol. 2024, Iss. 1, pp. 467-473
Closed Access | Times Cited: 1
Kerry A. Rogers, Jennifer A. Woyach
Hematology (2024) Vol. 2024, Iss. 1, pp. 467-473
Closed Access | Times Cited: 1
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia
Kerry A. Rogers
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. 685-687
Closed Access
Kerry A. Rogers
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. 685-687
Closed Access
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia
Andrew Lipsky, Nicole Lamanna
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Andrew Lipsky, Nicole Lamanna
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3
Elizabeth Schmitz, Abigail Ridout, Audrey L. Smith, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2857-2857
Open Access
Elizabeth Schmitz, Abigail Ridout, Audrey L. Smith, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2857-2857
Open Access
